Abstract

Drug discovery scientists often believe gram scale quantities of API are required to determine CMC properties like solubility, oral absorption, salt selection, and formulation strategy. But in this webinar, Crystal Pharmatech Co-Founder and Chief Business Officer Robert Wenslow present advanced computational approaches and a focused lab component to provide you with development risks with only 25mg of material. This allows developability to truly mainstream into late lead op and significantly enhance POS for Phase I candidates.

Speakers: Robert Wenslow & Andy Mueller